Anti-infectives are medicines such as antibiotics, antifungals, and antivirals that work to treat or prevent infections.
Since the 1940’s when Pfizer first mass-produced penicillin, we’ve been actively involved in the discovery and development of medicines to treat infections as well as vaccines that prevent them.
We have over 80 anti-infective medicines and vaccines in our portfolio, and continue to evaluate opportunities to expand our R&D pipeline to ensure we address the evolving medical needs of patients and healthcare workers. This includes helping to tackle antimicrobial resistance (AMR), where micro-organisms which cause infection (e.g. bacteria) survive exposure to a medicine that would normally kill them or stop their growth.
Raising awareness of antimicrobial resistance, viruses & pandemics, and the role of vaccines in schools across the UK.
Antimicrobial resistance (AMR) is one of the top global threats facing society and urgent action is critical to mitigate its impact.
We are incredibly proud to be partnering with NHS England, NICE and the UK government in piloting an innovative reimbursement model for antimicrobials.